Hyperion Defi (HYPD) Net Income towards Common Stockholders (2017 - 2026)
Hyperion Defi (HYPD) posted quarterly Net Income towards Common Stockholders of $3.2 million for Q1 2026, up 192.88% year-over-year from $1.1 million in Q1 2025, and up 107.98% quarter-over-quarter from -$40.6 million in Q4 2025.
Hyperion Defi (HYPD) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Hyperion Defi (HYPD) has reported Net Income towards Common Stockholders for 10 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 192.88% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at -$40.3 million (up 4.95% YoY), while the FY2025 annual figure was -$47.0 million, up 5.66% from the prior year.
- Net Income towards Common Stockholders climbed to $3.2 million in Q1 2026 per HYPD's latest filing, from -$40.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.8 million in Q3 2025 and bottomed at -$40.6 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$8.9 million across 5 years, with a median of -$7.4 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 277.34% — and 2026, when it surged 192.88%.
- Hyperion Defi's Net Income towards Common Stockholders stood at -$5.1 million in 2022, then plunged by 56.03% to -$7.9 million in 2023, then slumped by 151.45% to -$20.0 million in 2024, then tumbled by 103.25% to -$40.6 million in 2025, then jumped by 107.98% to $3.2 million in 2026.
- Business Quant data shows HYPD's Net Income towards Common Stockholders at $3.2 million in Q1 2026, -$40.6 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Hyperion Defi | 44.93 Mn | 35.29 Mn | 357,693.00 | 30.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.23 Mn |
| Mar 31, 2026 | 3.24 Mn |
| Dec 31, 2025 | -40.56 Mn |
| Sep 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | -8.79 Mn |
| Mar 31, 2025 | -3.48 Mn |
| Dec 31, 2024 | -19.95 Mn |
| Sep 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -11.05 Mn |
| Mar 31, 2024 | -12.14 Mn |
| Dec 31, 2023 | -7.94 Mn |
| Sep 30, 2023 | -6.99 Mn |
| Jun 30, 2023 | -8.33 Mn |
| Mar 31, 2023 | -5.91 Mn |
| Dec 31, 2022 | -5.09 Mn |
| Sep 30, 2022 | -7.41 Mn |
| Jun 30, 2022 | -7.27 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | 2.87 Mn |
| Sep 30, 2021 | -6.04 Mn |